Lakewood-Amedex Biotherapeutics, Inc. (LABT)
2.19
-0.03
(-1.35%)
USD |
NASDAQ |
Sep 14, 09:34
Lakewood-Amedex Biotherapeutics Enterprise Value : 0.3324M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 0.3324M |
| September 10, 2026 | -0.0363M |
| September 09, 2026 | 0.5493M |
| September 08, 2026 | 0.2457M |
| September 04, 2026 | -0.4051M |
| September 03, 2026 | -0.3617M |
| September 02, 2026 | 0.007M |
| September 01, 2026 | 1.504M |
| August 31, 2026 | 0.9398M |
| August 28, 2026 | 0.506M |
| August 27, 2026 | 0.9181M |
| August 26, 2026 | 0.8313M |
| August 25, 2026 | 0.4843M |
| August 24, 2026 | 0.1372M |
| August 21, 2026 | 0.3758M |
| August 20, 2026 | 0.2673M |
| August 19, 2026 | 0.3758M |
| August 18, 2026 | 0.506M |
| August 17, 2026 | 0.2023M |
| August 14, 2026 | 0.4409M |
| August 13, 2026 | 0.571M |
| August 12, 2026 | 0.6361M |
| August 11, 2026 | 0.6361M |
| August 10, 2026 | 0.6144M |
| August 07, 2026 | 0.3324M |
| Date | Value |
|---|---|
| August 06, 2026 | 0.3541M |
| August 05, 2026 | 0.5277M |
| August 04, 2026 | 0.3324M |
| August 03, 2026 | 0.2023M |
| July 31, 2026 | -0.1014M |
| July 30, 2026 | -0.2966M |
| July 29, 2026 | -0.1882M |
| July 28, 2026 | 0.0721M |
| July 27, 2026 | 0.9398M |
| July 24, 2026 | 1.244M |
| July 23, 2026 | 2.155M |
| July 22, 2026 | 2.914M |
| July 21, 2026 | -0.4485M |
| July 20, 2026 | -0.2966M |
| July 17, 2026 | -0.3834M |
| July 16, 2026 | -0.4702M |
| July 15, 2026 | 0.788M |
| July 14, 2026 | 1.048M |
| July 13, 2026 | 1.439M |
| July 10, 2026 | 1.178M |
| July 09, 2026 | 1.244M |
| July 08, 2026 | 0.6795M |
| July 07, 2026 | 0.7012M |
| July 06, 2026 | 1.460M |
| July 02, 2026 | 1.482M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
| Anixa Biosciences, Inc. | 80.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.772M |
| Total Expenses (Quarterly) | 3.772M |
| EPS Diluted (Quarterly) | -1.739 |
| Earnings Yield | -472.1% |